Bevacizumab biosimilar - Qilu Pharmaceutical

Drug Profile

Bevacizumab biosimilar - Qilu Pharmaceutical

Alternative Names: QL 1101

Latest Information Update: 29 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Qilu Pharmaceutical
  • Developer Qilu Pharmaceutical; Tianjin Medical University Cancer Institute and Hospital
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer

Most Recent Events

  • 25 May 2017 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, First-line therapy) in China (IV) (NCT03169335)
  • 01 Mar 2017 Phase-III clinical trials in Non-small cell lung cancer (Second-line therapy or greater, In adults, In the elderly, Late-stage disease) in China (IV) (NCT03195569)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top